An Tanghe
Research Subjects
Research Interests
An Tanghe has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Annelies Termont
1reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium
1 shared publicationFred Van Leuven
Experimental Genetics Group LEGTEGG, KULeuven, Campus Gasthuisberg ON1, 3000 Leuven, Belgium
1 shared publicationGerard Griffioen
1reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium
1 shared publicationHans-Ulrich Demuth
Probiodrug AG, Weinbergweg 22, 06120 Halle-Saale, Germany
1 shared publicationLouise Scrocchi
Amorfix Life Sciences Ltd., 3403 American Drive, Mississauga, ON, Canada L4V1T4
1 shared publicationPascal Merchiers
Ablynx NV, Technologiepark 214, 9052 Zwijnaarde-Gent, Belgium
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Hindawi Limited in International Journal of Alzheimer's Disease
- Vol. 2010, 1-9
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer's disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modified Abet species, are perceived as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deficits in orientation and memory that correlate in time with Abeta oligomerization and GSK3-mediated phosphorylation of endogenous murine Tau, all markers that have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic mouse model for preclinicalin vivotesting of candidate drugs are discussed.
- 1 January 2010
- Published by Hindawi Limited in International Journal of Alzheimer's Disease
- Vol. 2010, 1-9
Open AccessPathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer's disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modified Abet species, are perceived as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deficits in orientation and memory that correlate in time with Abeta oligomerization and GSK3-mediated phosphorylation of endogenous murine Tau, all markers that have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic mouse model for preclinicalin vivotesting of candidate drugs are discussed.